Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27376464 | 0.88 | ATAD2 (0.58) | ATAD2GRIN1GRIN2BBRD4DRD2 | |
| SCHEMBL30806763 | 0.88 | ATAD2 (0.58) | ATAD2GRIN1GRIN2BBRD4DRD2 | |
| SCHEMBL6636318 | 0.79 | HRH1 (0.43) | HSD17B10DRD2HRH1ACHE | |
| SCHEMBL14049720 | 0.76 | ATAD2 (0.65) | ATAD2DRD2DRD4DRD3 | |
| SCHEMBL3599801 | 0.75 | ATAD2 (0.68) | ATAD2HSD17B10DRD2DRD4DRD3 | |
| SCHEMBL16453538 | 0.75 | ATAD2 (0.78) | ATAD2HSD17B10DRD2DRD4DRD3 | |
| SCHEMBL17525607 | 0.75 | HSD17B10 (0.62) | HSD17B10GRM5HRH1CYP1A2ACHE | |
| SCHEMBL30806307 | 0.73 | POLB (0.68) | ATAD2BRD4DRD2DRD4DRD3 | |
| SCHEMBL27376419 | 0.73 | POLB (0.68) | ATAD2BRD4DRD2DRD4DRD3 | |
| SCHEMBL8138675 | 0.72 | ATAD2 (1.00) | ATAD2HSD17B10BRD4DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | ATAD2 1599/4885HSD17B10 148/4885GRIN1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.